New eczema drug candidate passes first safety hurdle in small trial
NCT ID NCT06193434
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tested an experimental drug called IBI356 in 99 healthy volunteers and people with atopic dermatitis (eczema). The main goal was to check if the drug is safe and how the body processes it. Participants received either a single dose, multiple doses, or a placebo. Results will help decide whether to move to larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI356 (an experimental drug given as an infusion)
What this could lead to
If this early trial shows IBI356 is safe, it could lead to larger studies testing whether it helps control atopic dermatitis (eczema) symptoms.
What could go wrong
This is a very early Phase 1 study focused on safety, not on whether the drug works. Many drugs fail in later stages, so it is far too soon to know if IBI356 will be effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Skin Disease Hospital
Shanghai, Shanghai Municipality, 200443, China